1-3 of 3
Hanry Yu
Close
Sort by
Journal Articles

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Jianbiao Zhou, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon, Zhigang Xie, Senthilnathan Palaniyandi, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen
Journal: Blood
Blood (2009) 113 (17): 4052–4062.
https://doi.org/10.1182/blood-2008-05-156422
Published: 2009
Includes: Supplemental data
Journal Articles

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou, MD, MS, Chonglei Bi, Bsc, Shaw-Cheng Liu, Wee-Joo Chng, MD, Kian-Ghee Tay, Bsc, Hanry Yu, Ph.D., Keith Glaser, Ph.D., Daniel Albert, PhD, BSc, Steven K Davidsen, Ph.D., Chien-Shing Chen, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1618.
https://doi.org/10.1182/blood.V112.11.1618.1618
Published: 2008
Journal Articles

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

Jianbiao Zhou, MD, MSc, Chonglei Bi, B.S., Lai Fong Poon, B.S., Viraj J. Janakakumara, B.S., Jiaying Khng, Hanry Yu, Ph.D., Keith B. Glaser, Ph.D., Daniel H. Albert, Ph.D., Davidsen K. Davidsen, Ph.D., Chien-Shing Chen, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 2367.
https://doi.org/10.1182/blood.V110.11.2367.2367
Published: 2007